Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Motixafortide,G-CSF
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : BioLineRx
Deal Size : $279.6 million
Deal Type : Licensing Agreement
BioLineRx Entered Exclusive License Agreement with Motixafortide in Asia, Advised by MSQ Ventures
Details : Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Brand Name : Aphexda
Molecule Type : Peptide
Upfront Cash : $29.6 million
October 31, 2023
Lead Product(s) : Motixafortide,G-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : BioLineRx
Deal Size : $279.6 million
Deal Type : Licensing Agreement
Details : YuTuo (zimberelimab) is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat, which is investigated for the treatment of metastatic cervical cancer.
Brand Name : YuTuo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 06, 2023
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Ligand Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.
Brand Name : GLS-010
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 30, 2021
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Ligand Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
